Tests are Continued
Selumetinib, an AstraZeneca investigational drug, MEK signaling pathway inhibitor preventing the tumor growth was granted the status of an orphan drug by the US Food and Drug Administration (FDA).
However, that drug did not pass phase III clinical trials for treatment of non-small-cell lung cancer (NSCLC). Selumetinib failed to achieve efficacy and safety endpoints in the clinical trial program.
Its effects for treatment of melanoma and eye cancer was not evidenced in the clinical trials.
Now the drug is being tested in phase III clinical trials in thyroid cancer patients at high risk of relapse. This drug may be effective for treatment of that disorder.